Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
delta-9-tetrahydrocannabinol + cannabidiol
- Development stage
- Phase 3
- Lead developer
- Grupo Español de Investigación en Neurooncología
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TN-TC11G is a combination drug containing delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). It works by binding to and activating type 1 and type 2 cannabinoid receptors (CB1 and CB2). The drug is being investigated for the treatment of newly-diagnosed glioblastoma in combination with standard treatments (temozolomide and radiotherapy).
- Brand names
- Nantheia ATL
- Other names
- THC+CBDTHC/CBD
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on delta-9-tetrahydrocannabinol + cannabidiol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on delta-9-tetrahydrocannabinol + cannabidiol.